🌿 Non-Stimulant Choice Substance Use History Simulator

Substance Use History as a Standard ADHD Intake Field

Every adult ADHD workup screens for prior substance use before any prescription.

• DAST-10 / ASSIST: Screening tools used (standard intake instruments)
• >90%: Adults screened routinely (in structured clinics)
• Lifetime: History window reviewed (not just recent months)
• High: Decision impact (shapes first prescription choice)

Why history screening comes first

Prescribing order depends on what the history reveals early.

What counts as a positive history

Any SUD diagnosis, misuse pattern, or diversion concern counts.

No Significant Substance Use History — Stimulants Remain Reasonable

Without SUD history, stimulants and non-stimulants are both on the table.

• 70–80%: Stimulant efficacy (response rate, typical)
• Yes: First-line status (per major guidelines)
• Often: Non-stimulant still offered (tolerability or preference)
• Low: Abuse-risk weight here (not a driving factor)

Stimulants as first-line therapy

Guidelines favor stimulants absent a competing risk factor.

When non-stimulants still get picked

Side effects, cardiac caution, or preference can still apply.

Positive SUD History — Abuse Potential Becomes a Primary Factor

A flagged history shifts the decision toward abuse-potential risk first.

• Elevated: Stimulant diversion risk (in SUD-positive patients)
• Primary: Relapse concern weight (now drives medication choice)
• High: Guideline caution level (stimulants deprioritized)
• Yes: Severity/recency considered (scales the caution level)

Abuse liability enters the equation

Reinforcing and euphoric potential now outweighs raw efficacy.

Recency and severity modulate caution

Recent, severe use raises caution more than remote, mild use.

Atomoxetine or Guanfacine — Chosen for Zero Abuse Liability

Non-stimulants lack reinforcing effects, removing the relapse-trigger concern.

• NRI: Atomoxetine mechanism (norepinephrine reuptake inhibitor)
• Alpha-2A agonist: Guanfacine mechanism (non-scheduled agent)
• None: Controlled-substance schedule (no DEA scheduling)
• Absent: Euphoric/reinforcing effect (no abuse liability)

Pharmacology behind the low abuse liability

No dopaminergic reward-circuit spike, unlike stimulant agents.

Trade-offs accepted for this patient group

Slower onset accepted in exchange for relapse-risk safety.

Effective ADHD Control Without Reintroducing Relapse Risk

Symptom control achieved while the stimulant relapse pathway stays closed.

• 50–65%: Non-stimulant efficacy (response rate, typical)
• Avoided: Relapse-risk pathway (no stimulant exposure)
• Ongoing: Long-term monitoring (symptom + recovery tracking)
• Favorable: Patient-specific outcome (goals met, risk contained)

Balancing efficacy against relapse risk

Good-enough control without reopening a relapse trigger wins.

Ongoing follow-up for this patient group

Periodic reassessment keeps the medication choice appropriate.